Company research
Replimune Group, Inc.
CIK 1737953Updated Sep 24, 2026
SecurityREPL · NASDAQ · equity
REPL price & chart
Loading TradingView…
NASDAQ:REPL on TradingView ↗About the company
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies, including the Company’s first commercially available product TUDRIQEVTM (vusolimogene oderparepvec-wtpg), approved under accelerated approval by the U.S. Food and Drug Administration in combination with nivolumab for the treatment of adults with advanced melanoma who experienced disease progression on a PD-1 antibody-based regimen. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and induce a systemic anti-tumor immune response. Upon intratumor injection, RPx causes direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens, alteration of the tumor microenvironment, and when dosed in combination with an immune checkpoint inhibitor immunotherapy, it may ignite a systemic anti-tumor response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety …
In the news
Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investors ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL ↗
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm ↗
Recent filings
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.03, 5.07, 9.01
4 filing
S-3ASR filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
4 filing
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
424B5 filing
Other Events
Items 8.01, 9.01
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 332,388,000Source | 551,328,000Source | 487,722,000Source | 646,591,000Source |
| Property, Plant and Equipment, NetUSD | 12,974,000Source | 13,739,000Source | 10,483,000Source | 7,479,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 209,024,000Source | 111,119,000Source | 74,457,000Source | 146,590,000Source |
| Assets, CurrentUSD | 279,119,000Source | 495,880,000Source | 433,667,000Source | 592,603,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 8,611,000Source | 8,351,000Source | 8,077,000Source | 6,278,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,270,000Source | 3,998,000Source | 4,635,000Source | 5,208,000Source |
| Other Assets, NoncurrentUSD | 2,942,000Source | 1,200,000Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 166,228,000Source | 135,485,000Source | 113,214,000Source | 91,299,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 82,000Source | 77,000Source | 61,000Source | 57,000Source |
| Additional Paid in CapitalUSD | 1,423,194,000Source | 1,358,897,000Source | 1,070,874,000Source | 1,034,994,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,262,519,000Source | -948,579,000Source | -701,282,000Source | -485,488,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 5,403,000Source | 5,448,000Source | 4,855,000Source | 5,729,000Source |
| Stockholders' Equity Attributable to ParentUSD | 166,160,000Source | 415,843,000Source | 374,508,000Source | 555,292,000Source |
| Liabilities and EquityUSD | 332,388,000Source | 551,328,000Source | 487,722,000Source | 646,591,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 58,228,000Source | 62,362,000Source | 40,438,000Source | 33,825,000Source |
| Operating Lease, Liability, CurrentUSD | 1,158,000Source | 1,184,000Source | 1,161,000Source | 1,118,000Source |
| Accounts Payable, CurrentUSD | 6,671,000Source | 12,463,000Source | 2,578,000Source | 5,364,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,328,000Source | 3,076,000Source | 3,771,000Source | 4,389,000Source |
| Other Liabilities, NoncurrentUSD | 455,000Source | 941,000Source | 786,000Source | 472,000Source |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 0Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 83,308,000Source | 46,377,000Source | 44,809,000Source | 28,648,000Source |
| Short-term InvestmentsUSD | 59,865,000Source | 372,685,000Source | 346,211,000Source | 436,796,000Source |
cash flow · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -313,940,000Source | -247,297,000Source | -215,794,000Source | -174,284,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 3,332,000Source | 3,502,000Source | 2,655,000Source | 2,447,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 32,272,000Source | 35,044,000Source | 34,125,000Source | 28,131,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -4,939,000Source | 9,941,000Source | -2,794,000Source | 1,981,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -280,344,000Source | -192,250,000Source | -185,467,000Source | -128,050,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 310,843,000Source | -23,796,000Source | 97,201,000Source | -142,502,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | 2,270,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 66,294,000Source | 252,396,000Source | 16,283,000Source | 311,303,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 97,905,000Source | 36,665,000Source | -72,069,000Source | 40,642,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 210,727,000Source | 112,822,000Source | 76,157,000Source | 148,226,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 4,688,000Source | 4,198,000Source | 3,044,000Source | 1,066,000Source |
| Income Taxes Paid, NetUSD | -5,000Source | 105,000Source | 300,000Source | 0Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,112,000Source | 315,000Source | -86,000Source | -109,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 32,272,000Source | 35,044,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 942,000Source | 201,000Source | 771,000Source | -5,676,000Source |
| General and Administrative ExpenseUSD | — | 72,180,000Source | 59,810,000Source | 50,553,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -314,491,000Source | -246,829,000Source | -215,386,000Source | -173,996,000Source |
| Income Tax Expense (Benefit)USD | -551,000Source | 468,000Source | 408,000Source | 288,000Source |
| Net Income (Loss) Attributable to ParentUSD | -313,940,000Source | -247,297,000Source | -215,794,000Source | -174,284,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -313,940,000Source | -247,297,000Source | -215,794,000Source | -174,284,000Source |
| Nonoperating Income (Expense)USD | 5,428,000Source | 14,798,000Source | 19,387,000Source | 3,084,000Source |
| Operating ExpensesUSD | 319,919,000Source | 261,627,000Source | 234,773,000Source | 177,080,000Source |
| Other Nonoperating Income (Expense)USD | -942,000Source | -202,000Source | 771,000Source | -5,676,000Source |
| Proceeds from Issuance of Common StockUSD | — | 155,728,000Source | 0Source | 149,854,000Source |
| Proceeds from Issuance of Long-term DebtUSD | 35,000,000Source | 0Source | 15,000,000Source | 28,154,000Source |
| Proceeds from Stock Options ExercisedUSD | 883,000Source | 267,000Source | 1,759,000Source | 3,444,000Source |
income statement · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | 98,735,000Source | — | — | — |
| Operating Income (Loss)USD | -319,919,000Source | -261,627,000Source | -234,773,000Source | -177,080,000Source |
| Other Nonoperating Income (Expense)USD | -942,000Source | -202,000Source | 771,000Source | -5,676,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -314,491,000Source | -246,829,000Source | -215,386,000Source | -173,996,000Source |
| Income Tax Expense (Benefit)USD | -551,000Source | 468,000Source | 408,000Source | 288,000Source |
| Net Income (Loss) Attributable to ParentUSD | -313,940,000Source | -247,297,000Source | -215,794,000Source | -174,284,000Source |
| Earnings Per Share, BasicUSD per share | -3.38Source | -3.07Source | -3.24Source | -2.99Source |
| Earnings Per Share, DilutedUSD per share | -3.38Source | -3.07Source | -3.24Source | -2.99Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 92,803,711Source | 80,564,147Source | 66,569,894Source | 58,213,010Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 92,803,711Source | 80,564,147Source | 66,569,894Source | 58,213,010Source |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 942,000Source | 201,000Source | 771,000Source | -5,676,000Source |
| General and Administrative ExpenseUSD | — | 72,180,000Source | 59,810,000Source | 50,553,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -314,491,000Source | -246,829,000Source | -215,386,000Source | -173,996,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -66,042,000Source | -25,870,000Source | -19,367,000Source | -18,367,000Source |
| Interest Expense, DebtUSD | 6,796,000Source | 5,775,000Source | 4,497,000Source | 1,963,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -313,940,000Source | -247,297,000Source | -215,794,000Source | -174,284,000Source |
| Nonoperating Income (Expense)USD | 5,428,000Source | 14,798,000Source | 19,387,000Source | 3,084,000Source |
| Operating ExpensesUSD | 319,919,000Source | 261,627,000Source | 234,773,000Source | 177,080,000Source |
| Research and Development ExpenseUSD | 221,184,000Source | 189,447,000Source | 174,963,000Source | 126,527,000Source |
Filing attachments
tm2623208d1_ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 tm2623208d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cash runway to support commercial launch and confirmatory trial Woburn, MA, August 14, 2026 - Replimune Group, Inc. (Nasdaq: REPL), a commerc…
Read attachment ↗tm2622780d1_ex4-1.htm · 8-K/A · 2026-08-11
EX-4.1 2 tm2622780d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 REPLIMUNE GROUP, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [●] (subject to adjustment) Warrant No. [●] Original Issue Date: [●], 2026 Replimune Group, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●] or its registered assigns (the “Holder”), is entitled, subject to the te…
Read attachment ↗tm2622673d1_ex4-1.htm · 8-K · 2026-08-10
EX-4.1 3 tm2622673d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 REPLIMUNE GROUP, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [●] (subject to adjustment) Warrant No. [●] Original Issue Date: [●], 2026 Replimune Group, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●] or its registered assigns (the “Holder”), is entitled, subject to the te…
Read attachment ↗tm2622673d1_ex99-1.htm · 8-K · 2026-08-10
EX-99.1 5 tm2622673d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Replimune Announces Pricing of $150.0 Million Underwritten Offering August 10, 2026 BOSTON, August 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL) (“Replimune”), a commercial-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the pricing of an underwritten offering of 9,701,490 shares of its common stock at an offering price of $12.06 per share and, in lieu …
Read attachment ↗tm2622487d1_ex99-1.htm · 8-K · 2026-08-07
EX-99.1 2 tm2622487d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen Broad label to address high unmet need in advanced melanoma Replimune will host conference call on August 6, 2026 at 4:30 p.m. ET. WOBURN, Mass., August 6, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology…
Read attachment ↗tm2622487d1_ex99-2.htm · 8-K · 2026-08-07
EX-99.2 3 tm2622487d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 © 2026 Replimune Group Inc. TUDRIQEV TM (vusolimogene oderparepvec - wtpg ) FDA Accelerated Approval Investor Call August 6, 2026 © 2026 Replimune Group Inc. TUDRIQEV TM Approval Call © 2026 Replimune Inc. 2 Safe Harbor Any statements contained herein that are not statements of historical facts may be deemed to be forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 2…
Read attachment ↗